Carcinomas Clinical Trial
Official title:
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).
OBJECTIVES Primary objective: To determine the objective response rate (ORR) of patients with locally advanced or metastatic RMC treated with combination nivolumab plus relatlimab. ORR is defined as the proportion of patients with a best response of complete response (CR) or partial response (PR) by the Response Evaluation Criteria. In Solid Tumors (RECIST 1.1) criteria recorded between Day 1 of the study and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever occurs first. Our goal is to significantly improve the ORR compared with the historical ORR of 29% achieved in our institution using conventional cytotoxic chemotherapies. Secondary objectives: - To determine the efficacy and safety of the combination of nivolumab plus relatlimab in patients with RMC. Efficacy will be measured by overall survival (OS), progression-free survival (PFS), time to ORR, duration of response, and the disease control rate (DCR). - To evaluate potential biomarkers for patient stratification and treatment response, as well as tumor antigen-specific immune responses, such as antibody and T cell responses, as surrogates for anti-tumor activity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06302569 -
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06161532 -
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
|
Phase 2 | |
| Completed |
NCT02601950 -
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
|
Phase 2 | |
| Enrolling by invitation |
NCT02875548 -
A Study to Assess the Long-term Safety of Tazemetostat
|
Phase 1/Phase 2 | |
| Completed |
NCT00027820 -
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04537715 -
Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer
|
Phase 1 | |
| No longer available |
NCT03874455 -
Tazemetostat Expanded Access Program for Adults With Solid Tumors
|